DIA_CENTRAL:T2D Treatment Pattern in Central Europe

NCT03807440 | Completed Results FDA Drug

• 1 other identifier: 1245-0187
• Study Type: observational
• Target: 4,083
• Locations: 5 countries
• Sites: 177

Brief Summary

This is a non-interventional study using existing data including medical chart review.

Conditions

Diabetes Mellitus, Type 2

Outcome Measures

Primary Outcomes (30)

• Number of Patients in Each Category of First Prescription of a Respective Modern Type 2 Diabetes (T2D) Medication According to Prescribing Specialist

  Number of patients in each category of prescription of a respective modern Type 2 Diabetes (T2D) medication according to prescribing specialist is reported.

  At study index date 1 (i.e. between September 2018 and December 2018).

• Number of Patients Initiated on a Modern Type 2 Diabetes (T2D) Medication Who Also Received Concomitant T2D Medications at Study Index Date 1 According to Prescribing Specialist

  Number of patients initiated on a modern type 2 diabetes (T2D) medication who also received concomitant T2D medications at study index date 1 according to prescribing specialist is reported. The concomitant T2D medications reported are: * Metformin * Sulfonylurea * Acarbose * Pioglitazone * Insulin * Others

  At study index date 1 (i.e. between September 2018 and December 2018).

• Number of Patients Initiated on a Modern Type 2 Diabetes (T2D) Medication Who Also Received Concomitant Cardiovascular Disease (CVD) and/or Chronic Kidney Disease (CKD) Medication at Study Index Date 1 According to Prescribing Specialist

  Number of patients initiated on a modern type 2 diabetes (T2D) medication who also received concomitant cardiovascular disease (CVD) and/or chronic kidney disease (CKD) medication at study index date 1 according to prescribing specialist is reported. The reported concomitant CVD and/or chronic CKD medications are: * Antihypertensive angiotensin-converting-enzyme inhibitors (ACEi) or angiotensin II receptor blockers (ARBs) * Statins * Low dose aspirin * Beta blockers * Diuretics * Others

  At study index date 1 (i.e. between September 2018 and December 2018).

• Baseline Characteristic: Age According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist

  Baseline characteristic: Age according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by endocrinologist is reported. Age for each patient was calculated by subtracting the year of birth from the year of registration (i.e. Year of registration - Year of birth). Year of registration was defined as the year the patients where initiated on T2D medication.

  At study index date 1 (i.e. between September 2018 and December 2018).

• Baseline Characteristic: Number of Patients in Each Category of Gender According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist

  Baseline characteristic: Number of patients in each category of gender according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by endocrinologist is reported. The reported categories of gender are: * Female * Male

  At study index date 1 (i.e. between September 2018 and December 2018).

• Baseline Characteristic: Body Mass Index (BMI) According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist

  Baseline characteristic: Body mass index (BMI) according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by endocrinologist is reported. Body mass index (BMI) is weight in kilograms divided by height in meters squared (kilogram/meter\^2 (kg/m\^2)).

  At study index date 1 (i.e. between September 2018 and December 2018).

• Baseline Characteristic: Number of Patients in Each Category of Race According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist

  Baseline characteristic: Number of patients in each category of race according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by endocrinologist is reported. The reported categories of race are: * Black * Non-black

  At study index date 1 (i.e. between September 2018 and December 2018).

• Baseline Characteristic: Age According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist

  Baseline characteristic: Age according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by diabetologist is reported. Age for each patient was calculated by subtracting the year of birth from the year of registration (i.e. Year of registration - Year of birth). Year of registration was defined as the year the patients where initiated on T2D medication.

  At study index date 1 (i.e. between September 2018 and December 2018).

• Baseline Characteristic: Number of Patients in Each Category of Gender According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist

  Baseline characteristic: Number of patients in each category of gender according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by diabetologist is reported. The reported categories of gender are: * Female * Male

  At study index date 1 (i.e. between September 2018 and December 2018).

• Body Mass Index (BMI) According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist

  Baseline characteristic: Body mass index (BMI) according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by diabetologist is reported. Body mass index (BMI) is weight in kilograms divided by height in meters squared (kilogram/meter\^2 (kg/m\^2)).

  At study index date 1 (i.e. between September 2018 and December 2018).

• Baseline Characteristic: Number of Patients in Each Category of Race According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist

  Baseline characteristic: Number of patients in each category of race according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by diabetologist is reported. The reported categories of race are: * Black * Non-black

  At study index date 1 (i.e. between September 2018 and December 2018).

• Baseline Characteristic: Age According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist

  Baseline characteristic: Age according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by cardiologist is reported. Age for each patient was calculated by subtracting the year of birth from the year of registration (i.e. Year of registration - Year of birth). Year of registration was defined as the year the patients where initiated on T2D medication.

  At study index date 1 (i.e. between September 2018 and December 2018).

• Baseline Characteristic: Number of Patients in Each Category of Gender According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist

  Baseline characteristic: Number of patients in each category of gender according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by cardiologist is reported. The reported categories of gender are: * Female * Male

  At study index date 1 (i.e. between September 2018 and December 2018).

• Body Mass Index (BMI) According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist

  Baseline characteristic: Body mass index (BMI) according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by cardiologist is reported. Body mass index (BMI) is weight in kilograms divided by height in meters squared (kilogram/meter\^2 (kg/m\^2)).

  At study index date 1 (i.e. between September 2018 and December 2018).

• Baseline Characteristic: Number of Patients in Each Category of Race According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist

  Baseline characteristic: Number of patients in each category of race according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by cardiologist is reported. The reported categories of race are: * Black * Non-black

  At study index date 1 (i.e. between September 2018 and December 2018).

• Time Since Diagnosis of Type 2 Diabetes (T2D) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist

  Time since diagnosis of type 2 diabetes (T2D) according to T2D medication for the patients who were initiated on T2D medication by endocrinologist is reported. Time since diagnosis of T2D (years) was calculated by subtracting the year of T2D diagnosis from the year of registration. Year of registration was defined as the year patients where initiated on T2D medication.

  At study index date 1 (i.e. between September 2018 and December 2018).

• Time Since Diagnosis of Type 2 Diabetes (T2D) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist

  Time since diagnosis of type 2 diabetes (T2D) according to T2D medication for the patients who were initiated on T2D medication by diabetologist is reported. Time since diagnosis of T2D (years) was calculated by subtracting the year of T2D diagnosis from the year of registration. Year of registration was defined as the year patients where initiated on T2D medication.

  At study index date 1 (i.e. between September 2018 and December 2018).

• Time Since Diagnosis of Type 2 Diabetes (T2D) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist

  Time since diagnosis of type 2 diabetes (T2D) according to T2D medication for the patients who were initiated on T2D medication by cardiologist is reported. Time since diagnosis of T2D (years) was calculated by subtracting the year of T2D diagnosis from the year of registration. Year of registration was defined as the year patients where initiated on T2D medication.

  At study index date 1 (i.e. between September 2018 and December 2018).

• Clinical Parameter Relevant for Type 2 Diabetes (T2D): Percentage of Glycosylated Hemoglobin (HbA1c [%]) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist

  Clinical parameter relevant for Type 2 Diabetes (T2D): Percentage of glycosylated hemoglobin (HbA1c \[%\]) according to T2D medication for the patients who were initiated on T2D medication by endocrinologist is reported.

  At study index date 1 (i.e. between September 2018 and December 2018).

• Clinical Parameter Relevant for T2D: Number of Patients in Each Category of Percentage of Glycosylated Hemoglobin (HbA1c) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist

  Clinical parameter relevant for Type 2 Diabetes (T2D): Number of patients in each category of percentage of glycosylated hemoglobin (HbA1c) according to T2D medication for the patients who were initiated on T2D medication by endocrinologist is reported. The reported categories of percentage (%) of glycosylated hemoglobin are: * \<8.5% * ≥8.5% * Missing

  At study index date 1 (i.e. between September 2018 and December 2018).

• Clinical Parameter Relevant for Type 2 Diabetes (T2D): Percentage of Glycosylated Hemoglobin (HbA1c [%]) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist

  Clinical parameter relevant for type 2 diabetes (T2D): Percentage of glycosylated hemoglobin (HbA1c \[%\]) according to T2D medication for the patients who were initiated on T2D medication by diabetologist is reported.

  At study index date 1 (i.e. between September 2018 and December 2018).

• Clinical Parameter Relevant for Type 2 Diabetes (T2D): Number of Patients in Each Category of Percentage of Glycosylated Hemoglobin (HbA1c) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist

  Clinical parameter relevant for type 2 diabetes (T2D): Number of patients in each category of percentage of glycosylated hemoglobin (HbA1c) according to T2D medication for the patients who were initiated on T2D medication by diabetologist is reported. The reported categories of percentage of glycosylated hemoglobin are: * \<8.5% * ≥8.5% * Missing

  At study index date 1 (i.e. between September 2018 and December 2018).

• Clinical Parameter Relevant for Type 2 Diabetes (T2D): Percentage of Glycosylated Hemoglobin (HbA1c [%]) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist

  Clinical parameter relevant for type 2 diabetes (T2D): Percentage of glycosylated hemoglobin (HbA1c \[%\]) according to T2D medication for the patients who were initiated on T2D medication by cardiologist is reported.

  At study index date 1 (i.e. between September 2018 and December 2018).

• Clinical Parameter Relevant for Type 2 Diabetes (T2D): Number of Patients in Each Category of Percentage of Glycosylated Hemoglobin (HbA1c) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist

  Clinical parameter relevant for type 2 diabetes (T2D): Number of patients in each category of percentage of glycosylated hemoglobin (HbA1c) according to T2D medication for the patients who were initiated on T2D medication by cardiologist is reported. The reported categories of percentage of glycosylated hemoglobin are: * \<8.5% * ≥8.5% * Missing

  At study index date 1 (i.e. between September 2018 and December 2018).

• 10-year Risk for Fatal Cardiovascular Disease (CVD) According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist

  10-year risk for fatal cardiovascular disease (CVD) according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by endocrinologist is reported. 10-year risk for fatal CVD was calculated according to the applying Systematic COronary Risk Evaluation (SCORE) Risk Chart (European Society of Cardiology) which takes into account patient´s age, gender, systolic blood pressure, smoking status, and total cholesterol value at index date 1. SCORE Risk Chart takes values from from 0% to 100%. SCORE Risk Chart values from 5% and upwards indicate a high 10-year risk for a fatal cardiovascular event.

  At study index date 1 (i.e. between September 2018 and December 2018).

• 10-year Risk for Fatal Cardiovascular Disease (CVD) According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist

  10-year risk for fatal cardiovascular disease (CVD) according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by diabetologist is reported. 10-year risk for fatal CVD was calculated according to the applying Systematic COronary Risk Evaluation (SCORE) Risk Chart (European Society of Cardiology) which takes into account patient´s age, gender, systolic blood pressure, smoking status, and total cholesterol value at index date 1. SCORE Risk Chart takes values from from 0% to 100%. SCORE Risk Chart values from 5% and upwards indicate a high 10-year risk for a fatal cardiovascular event.

  At study index date 1 (i.e. between September 2018 and December 2018).

• 10-year Risk for Fatal Cardiovascular Disease (CVD) According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist

  10-year risk for fatal cardiovascular disease (CVD) according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by cardiologist is reported. 10-year risk for fatal CVD was calculated according to the applying Systematic COronary Risk Evaluation (SCORE) Risk Chart (European Society of Cardiology) which takes into account patient´s age, gender, systolic blood pressure, smoking status, and total cholesterol value at index date 1. SCORE Risk Chart takes values from from 0% to 100%. SCORE Risk Chart values from 5% and upwards indicate a high 10-year risk for a fatal cardiovascular event.

  At study index date 1 (i.e. between September 2018 and December 2018).

• Number of Patients Per Type of Medical Specialty of Other Physicians Involved in Treatment Decision According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist

  Number of patients per type of medical specialty of other physicians involved in treatment decision according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by endocrinologist is reported.

  At study index date 1 (i.e. between September 2018 and December 2018).

• Number of Patients Per Type of Medical Specialty of Other Physicians Involved in Treatment Decision According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist

  Number of patients per type of medical specialty of other physicians involved in treatment decision according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by diabetologist is reported.

  At study index date 1 (i.e. between September 2018 and December 2018).

• Number of Patients Per Type of Medical Specialty of Other Physicians Involved in Treatment Decision According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist

  Number of patients per type of medical specialty of other physicians involved in treatment decision according to type 2 diabetes (T2D) medication for the patients who were initiated on T2D medication by cardiologist is reported.

  At study index date 1 (i.e. between September 2018 and December 2018).

Secondary Outcomes (40)

• Number of Patients With Any Type of Cardiovascular Disease (CVD)

  At study index date 1 (i.e. between September 2018 and December 2018).

• Number of Patients With Chronic Kidney Disease (CKD) by Physician's Assessment

  At study index date 1 (i.e. between September 2018 and December 2018).

• Number of Patients With Documentation of Estimated Glomerular Filtration Rate (eGFR) / Urine Albumin Creatinine Ratio (UACR) Status

  At study index date 1 (i.e. between September 2018 and December 2018).

• Number of Patients With Chronic Kidney Disease (CKD) by Estimated Glomerular Filtration Rate (eGFR) and Urine Albumin Creatinine Ratio (UACR) Status

  At study index date 1 (i.e. between September 2018 and December 2018).

• Number of Patients in Each Category of the Different Types of Cardiovascular Disease

  At study index date 1 (i.e. between September 2018 and December 2018).

Study Arms (1)

Subjects with Diabetes Mellitus, Type 2

Drug: Empagliflozin; Drug: Sodium Glucose Transporter 2 inhibitor; Drug: Dipeptidyl-peptidase 4 inhibitor; Drug: Glucagon-like peptide 1 agonist

Interventions

Empagliflozin DRUG

Empagliflozin

Also known as: Jardiance® Synjardy® Trajenta® Jentadueto®

Subjects with Diabetes Mellitus, Type 2

Sodium Glucose Transporter 2 inhibitor DRUG

Sodium Glucose Transporter 2 inhibitor

Also known as: Jardiance® Synjardy® Trajenta® Jentadueto®

Subjects with Diabetes Mellitus, Type 2

Dipeptidyl-peptidase 4 inhibitor DRUG

Dipeptidyl-peptidase 4 inhibitor

Also known as: Jardiance® Synjardy® Trajenta® Jentadueto®

Subjects with Diabetes Mellitus, Type 2

Glucagon-like peptide 1 agonist DRUG

Glucagon-like peptide 1 agonist

Also known as: Jardiance® Synjardy® Trajenta® Jentadueto®

Subjects with Diabetes Mellitus, Type 2

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adult patients (18 years of age or older) with Type 2 Diabetes diagnosis, naïve to treatment with empagliflozin or other Sodium Glucose Transporter 2 inhibitor (SGLT2i), DPP4i (Dipeptidyl-peptidase 4 inhibitor) or GLP1a (Glucagon-like peptide 1 agonist) at index date were chosen.

You may qualify if:

• Written informed consent prior to participation
• Female and male patients age ≥ 18 years
• Patients with T2D diagnosis
• Patients who have been newly initiated (first ever use) with empagliflozin or other Sodium Glucose Transporter 2 inhibitor (SGLT2i), Dipeptidyl-peptidase 4 inhibitor (DPP4i) or Glucagon-like peptide 1 agonist (GLP1a) between September 2018 and December 2018 (study index date 1)
• Patients have been naïve to treatment with empagliflozin or other Sodium Glucose Transporter 2 inhibitor (SGLT2i), Dipeptidyl-peptidase 4 inhibitor (DPP4i) or Glucagon-like peptide 1 agonist (GLP1a) at study index date 1

You may not qualify if:

• Patients age \< 18 years
• Patients with diagnosis of other types of diabetes than T2D
• Patients who do not provide written consent to the terms of the study

Sponsors & Collaborators

• Boehringer Ingelheim: lead

Study Sites (177)

MHAT "Julia Verevska-Byala" EOOD, Center Nr.: 35903

Byala, 7100, Bulgaria

Location

MC "Diamedical 2013" OOD, Center Nr.: 35902

Dimitrovgrad, 6400, Bulgaria

Location

MBAL- Dobrich AD, Center Nr.: 35916

Dobrich, 9300, Bulgaria

Location

Dr. T. K. Bacheva - ASMP-IP-E EOOD, Center Nr.: 35904

Dupnitsa, 2600, Bulgaria

Location

MHAT "Medline Clinic", Center Nr.: 35911

Plovdiv, 4000, Bulgaria

Location

MC Kuchuk Parij OOD, Center Nr.: 35906

Plovdiv, 4030, Bulgaria

Location

MC Saint Elisaveta-Rakovski EOOD, Center Nr.: 35909

Rakovski, 4150, Bulgaria

Location

"Medical Center-Razgrad"OOD, Center Nr.: 35910

Razgrad, 7200, Bulgaria

Location

DCC 1 - Russe EOOD, Center Nr.: 35905

Rousse, 7000, Bulgaria

Location

MBAL "Hadzhi Dimitar" OOD, Center Nr.: 35915

Sliven, 8800, Bulgaria

Location

MC Polimed AD, Center Nr.: 35907

Sofia, 1303, Bulgaria

Location

MC Gina - LZ SIMP EOOD, Center Nr.: 35918

Sofia, 1463, Bulgaria

Location

MC "Vitaclinic" EOOD, Center Nr.: 35901

Sofia, 1680, Bulgaria

Location

MC Kalimat EOOD, Center Nr.: 35914

Sofia, 1680, Bulgaria

Location

Acibadem City Clinic Medical Center Varna EOOD, Center Nr.: 35908

Varna, 9002, Bulgaria

Location

Michal Brada, Center Nr.: 42001

Beclav, 69002, Czechia

Location

Dr. Kovaová, Center Nr.: 42069

Beroun, 26656, Czechia

Location

Practice Dr. Alice Sýkorová, Center Nr.: 42057

Bílina, 418 01, Czechia

Location

MUDr. Alica Vesela, Center Nr.: 42030

Broumov, 55001, Czechia

Location

EUC Klinika eské Budjovice, Center Nr.: 42052

Eské Budjovice, 37001, Czechia

Location

Lékaský dm Géko, Center Nr.: 42059

Eské Budjovice, 37011, Czechia

Location

Barbara Buzová, Center Nr.: 42003

Havíov, 73601, Czechia

Location

Zaviatiová, Petra, Center Nr.: 42004

Havíov, 73601, Czechia

Location

Radana Syslová, Center Nr.: 42035

Hlušovice, 78314, Czechia

Location

Pavel Kasík, Center Nr.: 42046

Hoovice, 268 31, Czechia

Location

Practice Dr. Petr Maule, Center Nr.: 42054

Humpolec, 39601, Czechia

Location

Mediab Jihlava s.r.o., Center Nr.: 42066

Jihlava, 58601, Czechia

Location

Practice MUDr. Gita Markofová, Center Nr.: 42053

Karlovy Vary, 36066, Czechia

Location

Dr. Konená, Center Nr.: 42036

Karviná - Staré Msto, 73301, Czechia

Location

Practice Zdzislaw Wranka, Center Nr.: 42072

Karviná-Hranice, 73301, Czechia

Location

Pavel Tománek, Center Nr.: 42028

Kopivnice, 74221, Czechia

Location

DIABET HELP s.r.o., Center Nr.: 42058

Kralupy nad Vltavou, 27801, Czechia

Location

MUDr.Tomáš Edelsberger, Center Nr.: 42007

Krnov, 79401, Czechia

Location

Jitka Hasalová, Center Nr.: 42010

Kromiz, 76901, Czechia

Location

árka Drinková, Center Nr.: 42038

Lede Nad Sázavou, 58401, Czechia

Location

Martina Košková, Center Nr.: 42047

Mladá Boleslav, 29350, Czechia

Location

Dobromila Vykoupilová, Center Nr.: 42033

Nmice Nad Hanou, 79827, Czechia

Location

Karel Churavý, Center Nr.: 42005

Nový Jiín, 74101, Czechia

Location

árka Kubánková, Center Nr.: 42048

Nymburk, 28802, Czechia

Location

Agentura Science Pro spol. s.r.o., Center Nr.: 42002

Olomouc, 772 00, Czechia

Location

Anna Rancová, Center Nr.: 42025

Olomouc, 77900, Czechia

Location

Josef íný, Center Nr.: 42026

Opava, 74601, Czechia

Location

MUDr.Tomáš Hrdina, Center Nr.: 42015

Opono, 51773, Czechia

Location

Dr. Šeptáková, Center Nr.: 42074

Ostrava, 700 30, Czechia

Location

Practice Dr. René Turínek, Center Nr.: 42034

Ostrava, 70200, Czechia

Location

MUDr. Eva Raická, Center Nr.: 42024

Ostrava, 71000, Czechia

Location

Jitka Homolová, Center Nr.: 42012

Ostrava, 72880, Czechia

Location

Radka Nágelová, Center Nr.: 42020

Ostrava Poruba, 70800, Czechia

Location

AIDIN VK s.r.o., Center Nr.: 42017

Perov, 75301, Czechia

Location

MUDr. Vra Prýmková, Center Nr.: 42070

Píbram, 26101, Czechia

Location

Zdenk Jankovec, Center Nr.: 42044

Plze, 30100, Czechia

Location

Diabetologická a interní ambulance, Center Nr.: 42064

Podbrady, 29001, Czechia

Location

MUDr. Jana Houdová, Center Nr.: 42068

Prague, 10000, Czechia

Location

Practice Dr. Milena Peterková, Center Nr.: 42063

Prague, 12143, Czechia

Location

MUDr.Michala Pelikánová s.r.o., Center Nr.: 42055

Prague, 14000, Czechia

Location

Markéta Hovorková, Center Nr.: 42042

Prague, 14021, Czechia

Location

Jakub Hron, Center Nr.: 42043

Prague, 14300, Czechia

Location

Milan Fleka, Center Nr.: 42041

Prague, 15000, Czechia

Location

Jií Jón, Center Nr.: 42045

Prague, 15030, Czechia

Location

Practice Dr. Lucie Kufová, Center Nr.: 42062

Prague, 15030, Czechia

Location

Practice Dr. Ida Reissová, Center Nr.: 42056

Prague, 16300, Czechia

Location

Barbora Diepoltová, Center Nr.: 42037

Prague, 19014, Czechia

Location

Practice Dr. Petronela Janeková, Center Nr.: 42065

Rumburk, 40801, Czechia

Location

Practice Dr. Miroslav Lindovský, Center Nr.: 42051

Sokolov, 35601, Czechia

Location

Dana Fialkoviová, Center Nr.: 42040

Strakonice, 38601, Czechia

Location

Marek Frydrych, Center Nr.: 42008

Tebí, 674 01, Czechia

Location

Marek Frydrych, Center Nr.: 42077

Tebí, 674 01, Czechia

Location

Diabetologická ambulance s.r.o., Center Nr.: 42076

Uherské Hradišt, 68601, Czechia

Location

Dr. Hrmová, Center Nr.: 42073

Vlašim, 25801, Czechia

Location

Lubomír Kudlej, Center Nr.: 42050

Vrchlabí, 54301, Czechia

Location

AdiaMed s.r.o., Center Nr.: 42009

Vsetín, 75501, Czechia

Location

EUC Klinika Zlín a.s., Center Nr.: 42075

Zlín, 76001, Czechia

Location

Robin Urbánek, Center Nr.: 42029

Zlín, 76001, Czechia

Location

Bajcsy-Zsilinszky Kórház és Rendelintézet, Center Nr.: 36019

Budapest, 1106, Hungary

Location

Jahn Ferenc Dél-pesti Kórház és Rendelintézet, Center Nr.: 36014

Budapest, 1204, Hungary

Location

Debreceni Egyetem Klinikai Központ, Kardiológiai Klinika, Center Nr.: 36006

Debrecen, 4032, Hungary

Location

Kátai Gábor Kórház, Diabetológia Szakrendelés, Center Nr.: 36007

Karcag, 5300, Hungary

Location

Practice Dr. Lelkesi Anita, Center Nr.: 36013

Mátészalka, 4700, Hungary

Location

Nagyatádi Kórház, Center Nr.: 36021

Nagyatád, 7500, Hungary

Location

Nyírségi Diabetes Centrum, Center Nr.: 36024

Nyíregyháza, 4400, Hungary

Location

Dr. Wagner Zoltán, Center Nr.: 36020

Pécs, 7625, Hungary

Location

Siófoki Kórház Rendelintézet, Center Nr.: 36004

Siófok, 8600, Hungary

Location

Soproni Gyógyközpont, Center Nr.: 36018

Sopron, 9400, Hungary

Location

Gabinet Diabetologiczno- Internistyczny Katarzyna Wasilewska, Center Nr.: 48011

Biaystok, 15-591, Poland

Location

NZOZ DIAMED Sp. z o.o., Center Nr.: 48061

Czechowice-Dziedzice, 43-502, Poland

Location

Prywatny Gabinet Lekarski dr n. med. Joanna Sawer-Szewczyk, Center Nr.: 48055

Czyca, 99-100, Poland

Location

Zespó Opieki Zdrowotnej w czycy, Center Nr.: 48054

Czyca, 99-100, Poland

Location

NZOZ Sal Med, Center Nr.: 48047

Dzieroniów, 58-200, Poland

Location

Poradnia Diabetologiczna, Center Nr.: 48028

Gorlice, 38-300, Poland

Location

Indywidualna Specjalistyczna Praktyka Lekarska Piotr Piskozub Specjalista Diabetolog, Center Nr.: 48042

Jelenia Góra, 58-506, Poland

Location

NZOZ Poradnia Diabetologiczna, Center Nr.: 48038

Konin, 62-504, Poland

Location

Zakad Opieki Medycznej Sanatio; Sp. Z. o.o., Center Nr.: 48030

Krakow, 31-548, Poland

Location

Prywatny Gabinet Lekarski Tomasz Wierzykowski, Center Nr.: 48053

Kutno, 99-300, Poland

Location

Indywidualna Specjalistyczna Praktyka Lekarska Magorzata Poskoska-Lemaska, Center Nr.: 48035

Kwidzyn, 82-500, Poland

Location

Indywidualna Specjalistyczna Praktyka Lekarska Barbara Soróbka, Center Nr.: 48001

Legnica, 59-220, Poland

Location

Poradnia Cukrzycowa SP ZOZ w Lesku, Center Nr.: 48024

Lesko, 38-600, Poland

Location

Lumed Sp. z o.o., Center Nr.: 48032

Lubaczów, 37-600, Poland

Location

DIABETA-CARE Sp.z o.o., Center Nr.: 48008

Lubin, 59-300, Poland

Location

Poradnia Diabetologiczna Dr. mudziska, Center Nr.: 48013

Nako Nad Noteci, 89-100, Poland

Location

Alfa Specjalistyczne Gabinety Lekarskie Ewa Moroz, Center Nr.: 48007

Nowy Scz, 33-300, Poland

Location

Poradnia Diabetologiczna Dr. Adamczyk-Gajda, Center Nr.: 48031

Olenica, 56-400, Poland

Location

MED-ART Sp. z o.o., Center Nr.: 48052

Orzesze, 43-180, Poland

Location

Indywidualna Specjalistyczna Praktyka Lekarska Wiesawa Fischer, Center Nr.: 48020

Ostrów Wielkopolski, 63-400, Poland

Location

Prywatny Gabinet Lekarski azuka, Center Nr.: 48026

Parczew, 21-200, Poland

Location

Powiatowy Szpital Specjalistyczny w Stalowej Woli, Center Nr.: 48056

Stalowa Wola, 37-450, Poland

Location

Prywatny Gabinet Lekarski dr n. med. Piotr Gryglas, Center Nr.: 48059

Warsaw, 03-922, Poland

Location

Poradnia Diabetologiczna Szpitala Powiatowego w Wicborku, Center Nr.: 48003

Wicbork, 89-410, Poland

Location

Orodek Praktyka Lekarska Konrad Strzelczyk, Center Nr.: 48012

Woomin, 05-200, Poland

Location

Poradnia Diabetologiczna SPZZOZ w Wyszkowie, Center Nr.: 48067

Wyszków, 07-200, Poland

Location

Wojewódzka Poradnia dla Chorych na Cukrzyc, Center Nr.: 48025

Zabrze, 41-800, Poland

Location

Cardiomed, Center Nr.: 48019

Zielona Góra, 65-001, Poland

Location

Anturium, Center Nr.: 70036

Barnaul, 656043, Russia

Location

Central city hospital, Center Nr.: 70073

Bataysk, 346880, Russia

Location

Chelyabinsk regional clinical hospital, Center Nr.: 70069

Chelyabinsk, 454076, Russia

Location

Russian Medical Academy of Continuing Professional Education, Center Nr.: 70058

Irkutsk, 664049, Russia

Location

The First Republican Clinical Hospital of the Ministry of Health of the Udmurt Republic, Center Nr.: 70037

Izhevsk, 426039, Russia

Location

Central City Hospital No. 18, Center Nr.: 70051

Kazan', 420073, Russia

Location

Kemerovo regional clinical hospital named S.V. Belyaev, Center Nr.: 70008

Kemerovo, 50066, Russia

Location

City Polyclinic No. 16, Center Nr.: 70067

Khabarovsk, 680045, Russia

Location

Kirov Clinical Hospital No. 7 named after V.I. Yurlova, Center Nr.: 70089

Kirov, 610020, Russia

Location

Krai clinical hospital Nr. 1 named after prof. S.V. Ochapovskogo, Center Nr.: 70049

Krasnodar, 350086, Russia

Location

Lipetsk Regional Hospital, Center Nr.: 70046

Lipetsk, 398902, Russia

Location

SBIH Center for Speech Pathology and Neurorehabilitation MDH, Center Nr.: 70080

Moscow, 109240, Russia

Location

Clinical Hospital No. 85 of trhe Federal Biomedical Agency, Center Nr.: 70042

Moscow, 115409, Russia

Location

National Medical Research Center for Endocrinology, Center Nr.: 70025

Moscow, 117036, Russia

Location

City Polyclinic No. 22 of the Department of Healthcare of the Moscow City, Center Nr.: 70043

Moscow, 117218, Russia

Location

City Polyclinic No. 22 of the Department of Healthcare of the Moscow City, Center Nr.: 70045

Moscow, 117218, Russia

Location

Endocrinology Dispensary of the Moscow City Healthcare Department, Center Nr.: 70032

Moscow, 119034, Russia

Location

Endocrinology Dispensary of the Moscow City Healthcare Department, Center Nr.: 70041

Moscow, 119034, Russia

Location

Endocrinology Dispensary of the Moscow City Healthcare Department, Center Nr.: 70081

Moscow, 119034, Russia

Location

Endocrinology Dispensary of the Moscow City Healthcare Department, Center Nr.: 70084

Moscow, 119034, Russia

Location

Vessel Clinic, Center Nr.: 70011

Moscow, 125252, Russia

Location

City Polyclinic No 107 of the Moscow City Healthcare Department, Center Nr.: 70082

Moscow, 127273, Russia

Location

City Clinical Hospital named after V.V. Veresaeva of the Moscow Department of Health, Center Nr.: 70003

Moscow, 127644, Russia

Location

City Polyclinic No. 1, Center Nr.: 70074

Nal'chik, 360051, Russia

Location

City clinical hospital #12 of Sormovskiy district of Nizhniy Novgorod, Center Nr.: 70018

Nizhny Novgorod, 603003, Russia

Location

Privolzhsky Research Medical University, Center Nr.: 70085

Nizhny Novgorod, 603005, Russia

Location

Novokuznetsk City Clinical Hospital No. 1, Center Nr.: 70050

Novokuznetsk, 654027, Russia

Location

AVICENNA, Center Nr.: 70065

Novosibirsk, 630007, Russia

Location

City Clinical Polyclinic #16, Center Nr.: 70056

Novosibirsk, 630078, Russia

Location

Novosibirsk State Medical University, Center Nr.: 70059

Novosibirsk, 6300911, Russia

Location

AVICENNA, Center Nr.: 70064

Novosibirsk, 630099, Russia

Location

Penza regional clinical hospital named after N.N. Burdenko, Center Nr.: 70095

Penza, 440026, Russia

Location

Private Clinic Salon Roden, Center Nr.: 70086

Perm, 614000, Russia

Location

City clinical hospital 5, Center Nr.: 70057

Perm, 614010, Russia

Location

City clinical hospital 5, Center Nr.: 70070

Perm, 614010, Russia

Location

City polyclinic #16 of the City Rostov-on-Don, Center Nr.: 70027

Rostov-on-Don, 344092, Russia

Location

North-West State Medical University named after II. Mechnikov, Center Nr.: 70053

Saint Petersbug, 191015, Russia

Location

North-West State Medical University named after II. Mechnikov, Center Nr.: 70077

Saint Petersbug, 191015, Russia

Location

First Saint-Petersburg state medical university named after acad. I.P.Pavlov, Center Nr.: 70024

Saint Petersburg, 197022, Russia

Location

First Saint-Petersburg state medical university named after acad. I.P.Pavlov, Center Nr.: 70087

Saint Petersburg, 197022, Russia

Location

Medilux-TM, Center Nr.: 70005

Saint Petersburg, 197227, Russia

Location

V.A. Almazov National Medical Research Center, Center Nr.: 70071

Saint Petersburg, 197341, Russia

Location

AntMed, Center Nr.: 70034

Saint Petersburg, 197349, Russia

Location

Dr. Tsiberkin, Center Nr.: 70048

Saint Petersburg, 197349, Russia

Location

City Pokrovskaya Hospital, Center Nr.: 70022

Saint Petersburg, 199106, Russia

Location

Zabotlivyi Doktor, Center Nr.: 70016

Saint Petersburg, 966550, Russia

Location

Samara city polyclinic Nr. 9 of Oktyabrskiy district, Center Nr.: 70028

Samara, 443110, Russia

Location

Samara city consulting and diagnostic polyclinic nr. 14, Center Nr.: 70029

Samara, 443111, Russia

Location

Clinical Hospital of the Saratov city, Center Nr.: 70090

Saratov, 410004, Russia

Location

LLC clinic "Family Doctor", Center Nr.: 70093

Saratov, 410012, Russia

Location

Multifunctional Medical Clinic "Sova", Center Nr.: 70030

Saratov, 410056, Russia

Location

Regional Endocrinological Dispensary, Center Nr.: 70078

Stavropol, 355045, Russia

Location

Tyumen State Medical University, Center Nr.: 70066

Tyumen, 625023, Russia

Location

City clinical hospital, Center Nr.: 70019

Ufa, 450014, Russia

Location

City Polyclinic No.2, Center Nr.: 70062

Ulan-Ude, 670031, Russia

Location

Limited Liability Company "CENTER", Center Nr.: 70060

Vladivostok, 690017, Russia

Location

Regional Clinical Hospital No. 2, Center Nr.: 70092

Vladivostok, 690035, Russia

Location

Regional Clinical Hospital No. 2, Center Nr.: 70068

Vladivostok, 690105, Russia

Location

Volgograd Regional Clinical Hospital No. 3, Center Nr.: 70076

Volgograd, 400001, Russia

Location

Clinical Polyclinic No.28, Center Nr.: 70040

Volgograd, 400117, Russia

Location

Voronezh City Clinical Hospital #11, Center Nr.: 70035

Voronezh, 394042, Russia

Location

State budgetary institution "City polyclinic Nr. 4", Center Nr.: 70017

Voronezh, 394077, Russia

Location

State budgetary institution "City polyclinic Nr. 4", Center Nr.: 70033

Voronezh, 394077, Russia

Location

State budgetary institution "City polyclinic Nr. 4", Center Nr.: 70055

Voronezh, 394077, Russia

Location

Limited Liability Company "Uralsky Medical Center", Center Nr.: 70063

Yekaterinburg, 620102, Russia

Location

Scientific and Practical Center of Specialized Types of Medical Care "Uralskij Institute of Cardiology", Center Nr.: 70079

Yekaterinburg, 620144, Russia

Location

Related Publications (1)

• Prazny M, Suplotova L, Gumprecht J, Kamenov Z, Fulop T, Medvedchikov A, Rosenzweig D, Aleksandric M. Real-world characteristics, modern antidiabetic treatment patterns, and comorbidities of patients with type 2 diabetes in central and Eastern Europe: retrospective cross-sectional and longitudinal evaluations in the CORDIALLY(R) study. Cardiovasc Diabetol. 2022 Oct 8;21(1):203. doi: 10.1186/s12933-022-01631-4.

  PMID: 36209118 DERIVED

Related Links

• Related Info

MeSH Terms

Conditions

Diabetes Mellitus, Type 2

Interventions

empagliflozin; Sodium-Glucose Transporter 2 Inhibitors; Dipeptidyl-Peptidase IV Inhibitors

Condition Hierarchy (Ancestors)

Diabetes Mellitus; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases

Intervention Hierarchy (Ancestors)

Molecular Mechanisms of Pharmacological Action; Pharmacologic Actions; Chemical Actions and Uses; Hypoglycemic Agents; Physiological Effects of Drugs; Protease Inhibitors; Enzyme Inhibitors

Results Point of Contact

• Title: Boehringer Ingelheim, Call Center
• Organization: Boehringer Ingelheim

clintriage.rdg@boehringer-ingelheim.com

1-800-243-0127

Study Officials

• Alexey Medvedchikov, +43180105-7896

  Alexey.Medvedchikov@Boehringer-Ingelheim.com

  STUDY CHAIR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: RETROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 15, 2019
• First Posted: January 17, 2019
• Study Start: August 26, 2019
• Primary Completion: August 31, 2021
• Study Completion: August 31, 2021
• Last Updated: December 1, 2023
• Results First Posted: December 1, 2023

Record last verified: 2023-02

Data Sharing

• IPD Sharing: Will not share

Locations

BU (15); HU (10); CZ (58); PL (28); RU (66)